At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
In Brief
A Phase 2 clinical trial evaluating KTE-C19, Atezolizumab, and 2 other interventions for Refractory Diffuse Large B Cell Lymphoma. Completed, enrolled 37 participants across 5 sites.
Detailed Summary
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma (DLBCL). Participants who received an infusion of KTE-C19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968 (NCT05041309).
Study Details
Timeline
Interventions
A single infusion of KTE-C19 CAR-T cells administered intravenously
Administered intravenously
Administered intravenously
Administered intravenously